If you liked this article you might like

Pharmacy Benefit Managers Shouldn't Fret Initial Fallout from Mylan Fiasco
FTC Details Concerns on Generic Drug Company Mergers
Mylan Is Done Leaning on EpiPen Sales and That Could be a Big Problem
Teva Stock Gains, Leerink: Despite Patent Loss, No Generic Competition Until 2018